Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/08—Drugs for disorders of the urinary system of the prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/04—Antipruritics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
  • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/14—Decongestants or antiallergics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/02—Nutrients, e.g. vitamins, minerals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
  • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
• Ruxolitinib ((3 R)-3 -cyclopentyl-3 - [4-(7H-pyrrolo [2,3 -d]pyrimidin-4-yl)pyrazol- 1 - yl]propanenitrile) is the first FDA approved Janus kinase (JAK) inhibitor and is the only drug currently approved for treatment of myelofibrosis.
• the compound has been shown in the clinic to effectively reduce spleen volume and improve total symptom scores in patients suffering from myelofibrosis. See, e.g., Verstovsek, S., et al.
• ruxolitinib is a BCS Class I molecule with rapid oral absorption and a short half-life of about 3 hours. See, Shi et al, J. Clin. Pharmacol. 2012 Jun;52(6):809-18. Epub 2011 May 20. These properties result in a high peak/trough plasma concentration ratio in human subjects leading to multiple daily doses for optimal treatment, and potentially contributing to problems with patient compliance and unwanted side effects.
• Ruxolitinib therapy is often associated with the adverse events of thrombocytopenia
• Thrombocytopenia is dose-dependent and considered the dose-limiting toxic effect.
• the present invention is directed to a sustained-release dosage form comprising at least one active ingredient which is ruxolitinib, or a pharmaceutically acceptable salt thereof, wherein the ruxolitinib, or pharmaceutically acceptable salt thereof, is present in the dosage form in an amount of about 10 to about 60 mg on a free base basis.
• the present invention is further directed to a method of treating a disease associated with JAK activity in a patient in need thereof, comprising administering the sustained-release dosage form of the invention to said patient.
• Figure 1 shows a graph comparing plasma concentrations of ruxolitinib after administration of a single dose of either 25 mg immediate-release or 25 mg sustained-release formulation in fasted, healthy human subjects.
• Figure 2 shows a graph comparing spleen volume responders in the COMFORT -I immediate-release formulation study and the sustained-release study.
• Figure 3 shows a graph comparing total symptom scores in the COMFORT -I immediate-release formulation study and the sustained-release study.
• Figure 4 shows a graph comparing ruxolitinib steady state plasma concentrations in MF patients dosed with 25 mg immediate-release or 25 mg sustained-release formulations.
• the present invention provides, inter alia, an oral, sustained-release dosage form comprising ruxolitinib, or a pharmaceutically acceptable salt thereof, as an active ingredient.
• the dosage form can contain ruxolitinib, or a pharmaceutically acceptable salt thereof, in an amount of about 10 to about 60 mg, about 10 to about 40 mg, about 20 to about 40 mg, or about 20 to about 30 mg on a free base basis.
• the dosage form contains about 10 mg, about 12.5 mg, about 20 mg, about 25 mg, about 30 mg, about 37.5 mg, about 40 mg, about 50 mg, or about 60 mg on a free base basis.
• the dosage form contains about 25 mg of ruxolitinib on a free base basis.
• the phrase "on a free base basis" indicates that the amount of ruxolitinib or salt thereof in the dosage form is measured based on the molecular weight of ruxolitinib free base only, even when the actual active ingredient is a salt of ruxolitinib having a different molecular weight than the free base.
• the conversion factor for ruxolitinib phosphate salt to free base is 0.7575.
• the active ingredient is a pharmaceutically acceptable salt of ruxolitinib, such as the maleic acid salt, sulfuric acid salt, or phosphoric acid salt.
• the active ingredient is ruxolitinib phosphate (i.e., phosphoric acid salt of ruxolitinib).
• the dosage form of the invention comprises a sustained-release formulation of ruxolitinib, or a pharmaceutically acceptable salt thereof.
• sustained-release is used as generally understood in the art and refers to a formulation designed to slowly release the active ingredient into a patient after oral administration and to maintain an essentially steady, therapeutically effective plasma level of active ingredient over a relatively long period of time, such as about 8 to about 24 hours or longer.
• the dosage forms of the invention include a sustained-release matrix former.
• Example sustained-release matrix formers include cellulosic ethers such as hydroxypropyl methylcellulose (HPMC, hypromellose) which is a high viscosity polymer.
• the sustained- release dosage forms of the invention can include, for example, about 10 to about 30%, about 15 to about 25%, or about 18 to about 24 % by weight of hydroxypropyl methylcellulose(s). In some embodiments, the formulation has about 20 % by weight of one or more
• hydroxypropyl methylcelluloses In further embodiments, the formulation has about 22 % by weight of one or more hydroxypropyl methyl celluloses.
• Example hydroxypropyl methylcelluloses include Methocel K15M, Methocel K4M, and Methocel K100LV.
• the sustained-release dosage forms of the invention can further include one or more fillers, glidants, disintegrants, binders, or lubricants as inactive ingredients. Fillers can be present in the formulations in an amount of 0 to about 85 % by weight. In some
• the formulation has about 50 to about 80%, about 55 to about 75%, or about 60 to about 70% by weight of filler.
• fillers include lactose monohydrate, microcrystalline cellulose, starch 1500, and lactose anhydrous, or combinations thereof.
• the filler comprises microcrystalline cellulose, lactose monohydrate, or both.
• Lubricants can be present in the dosage forms of the invention in an amount of 0 to about 5% by weight.
• Non-limiting examples of lubricants include magnesium stearate, stearic acid (stearin), hydrogenated oil, polyethylene glycol, sodium stearyl fumarate, and glyceryl behenate.
• the formulations include magnesium stearate, stearic acid, or both.
• Glidants can be present in the dosage forms of the invention in an amount of 0 to about 5% by weight.
• Non-limiting examples of glidants include talc, colloidal silicon dioxide, and cornstarch.
• the glidant is colloidal silicon dioxide.
• Disintegrants can be present in the dosage forms of the invention in an amount of 0 to about 10% by weight.
• Non-limiting examples of disintegrants include croscarmellose sodium, crospovidone, starch, cellulose, and low substituted hydroxypropyl cellulose. Croscarmellose sodium is a preferred disintegrant.
• Film-coating agents can be present in an amount of 0 to about 5% by weight.
• Non- limiting illustrative examples of film-coating agents include hypromellose or polyvinyl alcohol based coating with titanium dioxide, talc and optionally colorants available in several commercially available complete coating systems.
• the dosage form of the invention includes a sustained-release formulation comprising about 12.2% ruxolitinib phosphate, about 20% hydroxypropyl methylcellulose, about 64.3% filler, about 2.5% lubricant, and about 1% glidant, all by weight.
• the dosage form of the invention includes a sustained-release formulation comprising about 12.2% ruxolitinib phosphate, about 22% hydroxypropyl methylcellulose, about 62.3% filler, about 2.5% lubricant, and about 1% glidant, all by weight.
• the dosage form of the invention includes a sustained-release formulation as set out below.
• the dosage form of the invention includes a sustained-release formulation as set out below.
• the dosage form of the invention includes a sustained-release formulation as set out below.
• dosage form is meant to refer to a physically discrete unit of sustained-release formulation of the invention to be administered to a patient.
• Example dosage forms include tablets, caplets, capsules, and the like, containing any of the sustained- release formulations described herein. Dosage forms can further include pharmaceutically acceptable coatings, pigments, or dyes.
• the dosage forms of the invention contain a sustained-release formulation that results in the relatively slow release of ruxolitinib once administered, characterized by particular pharmacokinetic parameters different from those of an immediate-release formulation.
• the sustained-release dosage forms of the invention can minimize potentially harmful spikes in drug plasma concentrations that are associated with immediate-release formulations, and can help provide continuous, steady, and therapeutically effective plasma levels of drug.
• the dosage forms of the invention can be administered to a human patient as needed for therapeutic efficacy against the disease being treated, for example, once daily.
• the dosage forms of the invention are administered to fasted patients.
• fasted means, in reference to a human patient or subject, that the patient or subject has not ingested food or drink (except water) for at least 3 hours prior to dosing. In some embodiments, patients are fasted for at least 10 hours prior to dosing.
• the dosage forms of the invention are administered to non- fasted human patients or subjects.
• Bioavailability of ruxolitinib is high (e.g., about 70-80%) and no food effect has been observed in immediate-release dosage forms. Accordingly, it is believed that the pharmacokinetics of ruxolitinib administered as a sustained-release dosage form would not be significantly different in fasted and non-fasted patients.
• administration of the sustained-release dosage form of the invention to a human results in a mean peak plasma concentration (C max ) of ruxolitinib of about 700 nM or less.
• administration of the sustained-release dosage form of the invention to a human results in a mean peak plasma concentration (C max ) of ruxolitinib of about 600 nM or less.
• administration of the sustained-release dosage form of the invention to a human results in a mean peak plasma concentration (C max ) of ruxolitinib of about 500 nM or less.
• administration of the sustained-release dosage form of the invention to a human results in a mean peak plasma concentration (C max ) of ruxolitinib of about 400 nM or less.
• administration of the sustained-release dosage form of the invention to a human results in a mean peak plasma concentration (C max ) of ruxolitinib of about 200 to about 700 nM.
• administration of the sustained-release dosage form of the invention to a human results in a mean peak plasma concentration (C max ) of ruxolitinib of about 200 to about 600 nM.
• administration of the sustained-release dosage form of the invention to a human results in a mean peak plasma concentration (C max ) of ruxolitinib of about 300 to about 500 nM. In some embodiments, administration of the sustained-release dosage form of the invention to a human results in a mean peak plasma concentration (C max ) of ruxolitinib of about 300 to about 400 nM.
• administration of the sustained-release dosage form of the invention to a human results a mean time to peak plasma concentration (T max ) of ruxolitinib of about 1.5 hours or more.
• administration of the sustained-release dosage form of the invention to a human results in a mean time to peak plasma concentration (T max ) of ruxolitinib of about 1.5 hours to about 5 hours.
• administration of the sustained-release dosage form of the invention to a human results in a mean time to peak plasma concentration (T max ) of ruxolitinib of about 2 hours to about 4 hours.
• administration of the sustained-release dosage form of the invention to a human results in a ratio of mean peak plasma concentration (C max ) to mean 12- hour plasma concentration (Cnh) of ruxolitinib of about 10 or less.
• administration of the sustained-release dosage form of the invention to a human results in a ratio of mean peak plasma concentration (C max ) to mean 12- hour plasma concentration (Cnh) of ruxolitinib of about 6 or less.
• administration of the sustained-release dosage form of the invention to a human results in a ratio of mean peak plasma concentration (C max ) to mean 12- hour plasma concentration (Ci 2 h) of ruxolitinib of about 5 or less.
• administration of the sustained-release dosage form of the invention to a human results in a ratio of mean peak plasma concentration (C max ) to mean 12- hour plasma concentration (Cnh) of ruxolitinib of about 4 or less.
• administration of the sustained-release dosage form of the invention to a human results in a ratio of mean peak plasma concentration (C max ) to mean 12- hour plasma concentration (Cnh) of ruxolitinib of about 1 to 10.
• administration of the sustained-release dosage form of the invention to a human results in a ratio of mean peak plasma concentration (C max ) to mean 12- hour plasma concentration (Cnh) of ruxolitinib of about 2 to 7.
• administration of the sustained-release dosage form of the invention to a human results in a mean half-life (t ⁇ ) of from about 3.5 hours to about 1 1 hours. In some embodiments, administration of the sustained-release dosage form of the invention to a human results in a mean half-life (t ⁇ ) of from about 4 hours to about 8 hours.
• administration of a single dose of a sustained-release dosage form of the invention to a human results in mean bioavailability (AUCo- ⁇ ) of ruxolitinib of at least about 3000 nM*h.
• administration of a single dose of a sustained-release dosage form of the invention to a human results in mean bioavailability (AUCo- ⁇ ) of ruxolitinib of at least about 3500 nM*h.
• administration of a single dose of a sustained-release dosage form of the invention to a human results in mean bioavailability (AUCo- ⁇ ) of ruxolitinib of about 3000 to about 4000 nM*h.
• administration of a single dose of a sustained-release dosage form of the invention to a human results in mean bioavailability (AUCo- ⁇ ) of ruxolitinib of about 3100 to about 3800 nM*h.
• the sustained-release dosage form of the invention has a mean relative bioavailability based on AUC of from about 65 % to about 1 10 % or about 75% to about 95% relative to an immediate release formulation comprising the same amount of ruxolitinib, or a pharmaceutically acceptable salt thereof, in patients.
• AUC can be, for example, AUCo- ⁇ (e.g., for a single dose) or AUCo-t where t is a specified time.
• mean when preceding a pharmacokinetic value (e.g. mean C max ) represents the arithmetic mean value of the pharmacokinetic value taken from a population of patients unless otherwise specified.
• C max means the maximum observed plasma concentration
• Ci2h refers to the plasma concentration measured at 12 hours from administration.
• T max refers to the time at which the maximum blood plasma concentration is observed.
• Tm refers to the time at which the plasma concentration is half of the observed maximum.
• AUC refers to the area under the plasma concentration-time curve which is a measure of total bioavailability.
• AUCo- ⁇ refers to the area under the plasma concentration-time curve extrapolated to infinity.
• AUCo-t refers to the area under the plasma concentration-time curve from time 0 to the last time point with a quantifiable plasma concentration, usually about 12- 36 hours.
• AUCo- T refers to the area under the plasma concentration-time curve from time 0 to the time of the next dose.
• sustained-release dosage forms of the invention have certain advantages over immediate-release dosage forms.
• the maintenance of steady, therapeutically effective plasma levels of ruxolitinib afforded by the sustained-release dosage forms of the invention allows for reduced dosing, such as doing only once per day, as opposed to twice or more for immediate-release forms.
• the reduced dosing can help with patient compliance in their treatment regimen.
• administration of the sustained-release dosage form of the invention to a human results in a therapeutically effective plasma level of ruxolitinib for at least about 8 hours, at least about 10 hours, at least about 12 hours, at least about 18, or at least about 24 hours.
• the sustained-release dosage form of the invention maintains a plasma level between about 75 and about 500 nM for at least about 8 hours, at least about 12 hours, or at least about 18 hours.
• the sustained-release dosage form of the invention maintains a plasma level between about 100 and about 400 nM for at least about 6 hours or at least about 8 hours.
• sustained-release dosage form e.g., containing 25 mg of ruxolitinib phosphate on a free base basis
• an immediate-release dosing regimen e.g. 15 mg or 20 mg BID.
• a sustained-release formulation of ruxolitinib could both maintain therapeutic efficacy and significantly reduce unwanted side effects related to thrombocytopenia or reduced hemoglobin levels.
• Clinical data related to efficacy and side effects in myelofibrosis patients for both sustained-release and immediate-release dosing is compared in the Examples.
• administration of the sustained-release dosage form of the invention to a human once daily for at least 16 weeks results in a mean decrease in mean base platelet count of no more than about 100 x 10 9 /L, no more than about 80 x 10 9 /L, no more than about 60 x 10 9 /L, or no more than about 40 x 10 9 /L.
• administration of the sustained-release dosage form of the invention to a human once daily for at least 16 weeks results in a mean decrease in mean base platelet count of between about 0 x 10 9 /L and about 100 x 10 9 /L, between about 30 x 10 9 /L and about 80 x 10 9 /L, or between about 50 x 10 9 /L and about 70 x 10 9 /L.
• administration of the sustained-release dosage form of the invention to a human once daily for at least 16 weeks results in a mean decrease in mean baseline hemoglobin (Hgb) of no more than about 15 g/L, no more than about 10 g/L, no more than about 8 g/L, or no more than about 6 g/L.
• Hgb mean baseline hemoglobin
• administration of the sustained-release dosage form of the invention to a human once daily for at least 16 weeks results in a mean decrease in mean baseline hemoglobin (Hgb) of about 0 to about 15 g/L, about 5 to about 15 g/L, about 2 to about 12 g/L, or about 5 to about 12 g/L.
• Hgb mean baseline hemoglobin
• the platelet counts and hemoglobin levels are measured in patients having received no blood transfusions during the treatment period.
• Mean baseline platelet counts and mean baseline hemoglobin levels are typically measured prior to the start of treatment.
• a JAK-associated disease can include any disease, disorder or condition that is directly or indirectly linked to expression or activity of the JAK, including overexpression and/or abnormal activity levels.
• a JAK-associated disease can also include any disease, disorder or condition that can be prevented, ameliorated, or cured by modulating JAK activity.
• JAK-associated diseases include diseases involving the immune system including, for example, organ transplant rejection (e.g., allograft rejection and graft versus host disease).
• Further examples of JAK-associated diseases include autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, juvenile arthritis, psoriatic arthritis, type I diabetes, lupus, psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, myasthenia gravis, immunoglobulin nephropathies, myocarditis, autoimmune thyroid disorders, chronic obstructive pulmonary disease (COPD), and the like.
• the autoimmune disease is an autoimmune bullous skin disorder such as pemphigus vulgaris (PV) or bullous pemphigoid (BP).
• JAK-associated diseases include allergic conditions such as asthma, food allergies, eszematous dermatitis, contact dermatitis, atopic dermatitis (atropic eczema), and rhinitis.
• JAK-associated diseases include viral diseases such as Epstein Barr Virus (EBV), Hepatitis B, Hepatitis C, HIV, HTLV 1, Varicella-Zoster Virus (VZV) and Human Papilloma Virus (HPV).
• EBV Epstein Barr Virus
• Hepatitis B Hepatitis C
• HIV HTLV 1
• VZV Varicella-Zoster Virus
• HPV Human Papilloma Virus
• JAK-associated disease examples include diseases associated with cartilage turnover, for example, gouty arthritis, septic or infectious arthritis, reactive arthritis, reflex sympathetic dystrophy, algodystrophy, Tietze syndrome, costal athropathy, osteoarthritis deformans endemica, Mseleni disease, Handigodu disease, degeneration resulting from fibromyalgia, systemic lupus erythematosus, scleroderma, or ankylosing spondylitis.
• diseases associated with cartilage turnover for example, gouty arthritis, septic or infectious arthritis, reactive arthritis, reflex sympathetic dystrophy, algodystrophy, Tietze syndrome, costal athropathy, osteoarthritis deformans endemica, Mseleni disease, Handigodu disease, degeneration resulting from fibromyalgia, systemic lupus erythematosus, scleroderma, or ankylosing spondylitis.
• JAK-associated disease examples include congenital cartilage
• malformations including hereditary chrondrolysis, chrondrodysplasias, and
• pseudochrondrodysplasias e.g., microtia, enotia, and metaphyseal chrondrodysplasia.
• JAK-associated diseases or conditions include skin disorders such as psoriasis (for example, psoriasis vulgaris), atopic dermatitis, skin rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis).
• skin disorders such as psoriasis (for example, psoriasis vulgaris), atopic dermatitis, skin rash, skin irritation, skin sensitization (e.g., contact dermatitis or allergic contact dermatitis).
• certain substances including some pharmaceuticals when topically applied can cause skin sensitization.
• co-administration or sequential administration of at least one JAK inhibitor of the invention together with the agent causing unwanted sensitization can be helpful in treating such unwanted sensitization or dermatitis.
• the skin disorder is treated by topical administration of at least one JAK inhibitor of the invention.
• the JAK-associated disease is cancer including those characterized by solid tumors (e.g., prostate cancer, renal cancer, hepatic cancer, pancreatic cancer, gastric cancer, breast cancer, lung cancer, cancers of the head and neck, thyroid cancer, glioblastoma, Kaposi's sarcoma, Castleman's disease, uterine leiomyosarcoma, melanoma etc.), hematological cancers (e.g., lymphoma, leukemia such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML) or multiple myeloma), and skin cancer such as cutaneous T-cell lymphoma (CTCL) and cutaneous B-cell lymphoma.
• CTCLs include Sezary syndrome and mycosis fungoides.
• the JAK inhibitors described herein, or in combination with other JAK inhibitors, such as those reported in U.S. Ser. No. 1 1/637,545, which is incorporated herein by reference in its entirety, can be used to treat inflammation-associated cancers.
• the cancer is associated with inflammatory bowel disease.
• the inflammatory bowel disease is ulcerative colitis.
• the inflammatory bowel disease is Crohn's disease.
• the inflammation-associated cancer is colitis-associated cancer.
• the inflammation-associated cancer is colon cancer or colorectal cancer.
• the cancer is gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), adenocarcinoma, small intestine cancer, or rectal cancer.
• JAK-associated diseases can further include those characterized by expression of: JAK2 mutants such as those having at least one mutation in the pseudo-kinase domain (e.g., JAK2V617F); JAK2 mutants having at least one mutation outside of the pseudo-kinase domain; JAK1 mutants; JAK3 mutants; erythropoietin receptor (EPOR) mutants; or deregulated expression of CRLF2.
• JAK2 mutants such as those having at least one mutation in the pseudo-kinase domain (e.g., JAK2V617F); JAK2 mutants having at least one mutation outside of the pseudo-kinase domain; JAK1 mutants; JAK3 mutants; erythropoietin receptor (EPOR) mutants; or deregulated expression of CRLF2.
• JAK-associated diseases can further include myeloproliferative disorders (MPDs) such as polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis
• MPDs myeloproliferative disorders
• PV polycythemia vera
• ET essential thrombocythemia
• the myeloproliferative disorder is myelofibrosis (e.g., primary myelofibrosis (PMF) or post polycythemia vera/essential thrombocythemia myelofibrosis (Post-PV/ET MF)). In some embodiments, the myeloproliferative disorder is post-essential thrombocythemia myelofibrosis (Post-ET MF). In some embodiments, the
• myeloproliferative disorder is post polycythemia vera myelofibrosis (Post-PV MF).
• the present invention further provides methods of treating psoriasis or other skin disorders by administration of a topical formulation containing a compound of the invention.
• sustained-release formulation and dosage forms described herein can be used to treat pulmonary arterial hypertension.
• the sustained-release formulation and dosage forms described herein can be used to treat mast cell activation syndrome.
• the present invention further provides a method of treating dermatological side effects of other pharmaceuticals by administration of the sustained-release dosage form of the invention.
• numerous pharmaceutical agents result in unwanted allergic reactions which can manifest as acneiform rash or related dermatitis.
• compositions that have such undesirable side effects include anti-cancer drugs such as gefitinib, cetuximab, erlotinib, and the like.
• anti-cancer drugs such as gefitinib, cetuximab, erlotinib, and the like.
• the dosage form of the invention can be administered in combination with (e.g., simultaneously or sequentially) the pharmaceutical agent having the undesirable dermatological side effect.
• JAK-associated diseases include inflammation and inflammatory diseases.
• Example inflammatory diseases include sarcoidosis, inflammatory diseases of the eye (e.g., crizis, uveitis, scleritis, conjunctivitis, or related disease), inflammatory diseases of the respiratory tract (e.g., the upper respiratory tract including the nose and sinuses such as rhinitis or sinusitis or the lower respiratory tract including bronchitis, chronic obstructive pulmonary disease, and the like), inflammatory myopathy such as myocarditis, and other inflammatory diseases.
• the inflammation disease of the eye is blepharitis.
• the sustained-release dosage forms herein can further be used to treat ischemia reperfusion injuries or a disease or condition related to an inflammatory ischemic event such as stroke or cardiac arrest.
• the sustained-release dosage forms described herein can further be used to treat endotoxin-driven disease state (e.g., complications after bypass surgery or chronic endotoxin states contributing to chronic cardiac failure).
• the sustained-release dosage forms described herein can further be used to treat anorexia, cachexia, or fatigue such as that resulting from or associated with cancer.
• the sustained-release dosage forms described herein can further be used to treat restenosis, sclerodermitis, or fibrosis.
• the sustained-release dosage forms described herein can further be used to treat conditions associated with hypoxia or astrogliosis such as, for example, diabetic retinopathy, cancer, or neurodegeneration. See, e.g., Dudley, A.C. et al. Biochem. J. 2005, 390(Pt 2):427-36 and Sriram, K. et al. J. Biol. Chem. 2004, 279(19): 19936-47. Epub 2004 Mar 2, both of which are incorporated herein by reference in their entirety.
• the sustained-release dosage forms described herein can be used to treat Alzheimer's disease.
• the sustained-release dosage forms described herein can further be used to treat other inflammatory diseases such as systemic inflammatory response syndrome (SIRS) and septic shock.
• SIRS systemic inflammatory response syndrome
• the sustained-release dosage forms described herein can further be used to treat gout and increased prostate size due to, e.g., benign prostatic hypertrophy or benign prostatic hyperplasia.
• JAK-associated diseases include bone resorption diseases such as
• Bone resorption can also be associated with other conditions such as hormonal imbalance and/or hormonal therapy, autoimmune disease (e.g. osseous sarcoidosis), or cancer (e.g. myeloma).
• autoimmune disease e.g. osseous sarcoidosis
• cancer e.g. myeloma
• the reduction of the bone resorption due to the JAK inhibitors can be about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90%.
• sustained-release dosage forms described herein can further be used to treat a dry eye disorder.
• dry eye disorder is intended to encompass the disease states summarized in a recent official report of the Dry Eye Workshop (DEWS), which defined dry eye as "a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.”
• DEWS Dry Eye Workshop
• the dry eye disorder is selected from aqueous tear-deficient dry eye (ADDE) or evaporative dry eye disorder, or appropriate combinations thereof.
• the dry eye disorder is Sjogren syndrome dry eye (SSDE).
• the dry eye disorder is non-Sjogren syndrome dry eye (NSSDE).
• the present invention provides a method of treating conjunctivitis, uveitis (including chronic uveitis), chorioditis, retinitis, cyclitis, sclieritis, episcleritis, or ulceris; treating inflammation or pain related to corneal transplant, LASIK (laser assisted in situ keratomileusis), photorefractive keratectomy, or LASEK (laser assisted sub-epithelial keratomileusis); inhibiting loss of visual acuity related to corneal transplant, LASIK, photorefractive keratectomy, or LASEK; or inhibiting transplant rejection in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the compound of the invention, or a pharmaceutically acceptable salt thereof.
• sustained-release dosage forms of the invention can be used to treat respiratory dysfunction or failure associated with viral infection, such as influenza and SARS.
• the term "individual,” “subject,” or “patient,” refers to a human, who can be fasted or un-fasted when the dosage form of the invention is administered.
• pharmaceutically acceptable refers to those compounds, materials, compositions and/or dosage forms, which are, within the scope of sound medical judgment, suitable for contact humans without excessive toxicity, irritation, allergic response and other problem complications commensurate with a reasonable benefit/risk ratio.
• the term "treating" or “treatment” refers to one or more of (1) preventing the disease; for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease; (2) inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., arresting further development of the pathology and/or symptomatology); and (3) ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (i.e., reversing the pathology and/or symptomatology) such as decreasing the severity of disease.
• preventing the disease for example, preventing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of
• One or more additional pharmaceutical agents such as, for example,
• chemotherapeutics anti-inflammatory agents, steroids, immunosuppressants, as well as Bcr- Abl, Flt-3, RAF and FAK kinase inhibitors such as, for example, those described in WO 2006/056399, which is incorporated herein by reference in its entirety, or other agents can be used in combination with the sustained-release dosage forms described herein for treatment of JAK-associated diseases, disorders or conditions.
• additional agents such as, for example, those described in WO 2006/056399, which is incorporated herein by reference in its entirety, or other agents can be used in combination with the sustained-release dosage forms described herein for treatment of JAK-associated diseases, disorders or conditions.
• additional agents such as, for example, those described in WO 2006/056399, which is incorporated herein by reference in its entirety, or other agents can be used in combination with the sustained-release dosage forms described herein for treatment of JAK-associated diseases, disorders or conditions.
• pharmaceutical agents can be administered to a patient simultaneously or sequentially.
• Example chemotherapeutics include proteosome inhibitors (e.g., bortezomib), thalidomide, revlimid, and DNA-damaging agents such as melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide, carmustine, and the like.
• proteosome inhibitors e.g., bortezomib
• thalidomide thalidomide
• revlimid thalidomide
• DNA-damaging agents such as melphalan, doxorubicin, cyclophosphamide, vincristine, etoposide, carmustine, and the like.
• Example steroids include coriticosteroids such as dexamethasone or prednisone.
• Example Bcr-Abl inhibitors include the compounds, and pharmaceutically acceptable salts thereof, of the genera and species disclosed in U.S. Pat. No. 5,521, 184, WO 04/005281, and U.S. Ser. No. 60/578,491, all of which are incorporated herein by reference in their entirety.
• Example suitable Flt-3 inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 03/037347, WO 03/099771, and WO 04/046120, all of which are incorporated herein by reference in their entirety.
• Example suitable RAF inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 00/09495 and WO 05/028444, both of which are incorporated herein by reference in their entirety.
• Example suitable FAK inhibitors include compounds, and their pharmaceutically acceptable salts, as disclosed in WO 04/080980, WO 04/056786, WO 03/024967, WO 01/064655, WO 00/053595, and WO 01/014402, all of which are incorporated herein by reference in their entirety.
• one or more of the compounds of the invention can be used in combination with one or more other kinase inhibitors including imatinib, particularly for treating patients resistant to imatinib or other kinase inhibitors.
• one or more JAK inhibitors of the invention can be used in combination with a chemotherapeutic in the treatment of cancer, such as multiple myeloma, and may improve the treatment response as compared to the response to the chemotherapeutic in the treatment of cancer, such as multiple myeloma, and may improve the treatment response as compared to the response to the chemotherapeutic in the treatment of cancer, such as multiple myeloma, and may improve the treatment response as compared to the response to the
• chemotherapeutic agent alone, without exacerbation of its toxic effects.
• additional pharmaceutical agents used in the treatment of multiple myeloma can include, without limitation, melphalan, melphalan plus prednisone [MP], doxorubicin, dexamethasone, and Velcade (bortezomib).
• Further additional agents used in the treatment of multiple myeloma include Bcr-Abl, Flt-3, RAF and FAK kinase inhibitors. Additive or synergistic effects are desirable outcomes of combining a JAK inhibitor of the present invention with an additional agent.
• agents such as dexamethasone may be reversible upon treatment with a JAK inhibitor of the present invention.
• the agents can be combined with the present compounds in a single or continuous dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.
• a corticosteroid such as dexamethasone is administered to a patient in combination with at least one JAK inhibitor where the dexamethasone is administered intermittently as opposed to continuously.
• combinations of sustained-release dosage forms with other therapeutic agents can be administered to a patient prior to, during, and/or after a bone marrow transplant or stem cell transplant.
• the additional therapeutic agent is fluocinolone acetonide (Retisert®), or rimexolone (AL-2178, Vexol, Alcon).
• the additional therapeutic agent is cyclosporine (Restasis®). In some embodiments, the additional therapeutic agent is a corticosteroid. In some embodiments, the corticosteroid is triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, or flumetholone.
• the additional therapeutic agent is selected from DehydrexTM (Holies Labs), Civamide (Opko), sodium hyaluronate (Vismed, Lantibio/TRB Chemedia), cyclosporine (ST-603, Sirion Therapeutics), ARG101(T) (testosterone, Argentis),
• AGR1012(P) (Argentis), ecabet sodium (Senju-Ista), gefarnate (Santen), 15-(s)- hydroxyeicosatetraenoic acid (15(S)-HETE), cevilemine, doxycycline (ALTY-0501, Alacrity), minocycline, iDestrinTM (NP50301, Nascent Pharmaceuticals), cyclosporine A (Nova22007, Novagali), oxytetracycline (Duramycin, MOLI1901, Lantibio), CF101
• dehydroepiandrosterone anakinra, efalizumab, mycophenolate sodium, etanercept (Embrel®), hydroxychloroquine, NGX267 (TorreyPines Therapeutics), actemra, gemcitabine, oxaliplatin, L-asparaginase, or thalidomide.
• the additional therapeutic agent is an anti-angiogenic agent, cholinergic agonist, TRP-1 receptor modulator, a calcium channel blocker, a mucin secretagogue, MUC 1 stimulant, a calcineurin inhibitor, a corticosteroid, a P2Y2 receptor agonist, a muscarinic receptor agonist, an mTOR inhibitor, another JAK inhibitor, Bcr-Abl kinase inhibitor, Flt-3 kinase inhibitor, RAF kinase inhibitor, and FAK kinase inhibitor such as, for example, those described in WO 2006/056399, which is incorporated herein by reference in its entirety.
• the additional therapeutic agent is a tetracycline derivative (e.g., minocycline or doxycline). In some embodiments, the additional therapeutic agent binds to FKBP 12. In some embodiments, the additional therapeutic agent is an alkylating agent or DNA cross-linking agent; an anti-metabolite/demethylating agent (e.g., 5-flurouracil, capecitabine or azacitidine); an anti-hormone therapy (e.g., hormone receptor antagonists, SERMs, or aromotase inhibitor); a mitotic inhibitor (e.g. vincristine or paclitaxel); an topoisomerase (I or II) inhibitor (e.g.
• an anti-metabolite/demethylating agent e.g., 5-flurouracil, capecitabine or azacitidine
• an anti-hormone therapy e.g., hormone receptor antagonists, SERMs, or aromotase inhibitor
• a mitotic inhibitor e.g. vincri
• mitoxantrone and irinotecan an apoptotic inducers (e.g. ABT-737); a nucleic acid therapy (e.g. antisense or R Ai); nuclear receptor ligands (e.g., agonists and/or antagonists: all-trans retinoic acid or bexarotene); epigenetic targeting agents such as histone deacetylase inhibitors (e.g. vorinostat), hypomethylating agents (e.g. decitabine); regulators of protein stability such as Hsp90 inhibitors, ubiquitin and/or ubiquitin like conjugating or deconjugating molecules; or an EGFR inhibitor (erlotinib).
• apoptotic inducers e.g. ABT-737
• a nucleic acid therapy e.g. antisense or R Ai
• nuclear receptor ligands e.g., agonists and/or antagonists: all-trans retinoic acid or bexaroten
• the additional therapeutic agent(s) are demulcent eye drops (also known as "artificial tears"), which include, but are not limited to, compositions containing polyvinylalcohol, hydroxypropyl methylcellulose, glycerin, polyethylene glycol (e.g. PEG400), or carboxymethyl cellulose. Artificial tears can help in the treatment of dry eye by compensating for reduced moistening and lubricating capacity of the tear film.
• the additional therapeutic agent is a mucolytic drug, such as N-acetyl- cysteine, which can interact with the mucoproteins and, therefore, to decrease the viscosity of the tear film.
• the additional therapeutic agent includes an antibiotic, antiviral, antifungal, anesthetic, anti-inflammatory agents including steroidal and nonsteroidal anti-inflammatories, and anti-allergic agents.
• suitable medicaments include aminoglycosides such as amikacin, gentamycin, tobramycin, streptomycin, netilmycin, and kanamycin; fluoroquinolones such as ciprofloxacin, norfloxacin, ofloxacin, trovafloxacin, lomefloxacin, levofloxacin, and enoxacin; naphthyridine; sulfonamides;
• polymyxin polymyxin; chloramphenicol; neomycin; paramomycin; colistimethate; bacitracin;
• vancomycin vancomycin; tetracyclines; rifampin and its derivatives ("rifampins"); cycloserine; beta- lactams; cephalosporins; amphotericins; fluconazole; flucytosine; natamycin; miconazole; ketoconazole; corticosteroids; diclofenac; flurbiprofen; ketorolac; suprofen; cromolyn;
• lodoxamide lodoxamide; levocabastin; naphazoline; antazoline; pheniramine; or azalide antibiotic.
• a 25 mg sustained-release formulation of ruxolitinib phosphate was prepared according to the following protocol.
• the formulation components are provided in Table 1 a. Percentages are by weight.
• conversion factor for phosphate salt to free base is 0.7575.
• Step 1 Add microcrystalline cellulose, ruxolitinib phosphate, lactose monohydrate, and hypromelloses to a suitable blender and mix.
• Step 2 Transfer the mix from Step 1 to a suitable granulator and mix.
• Step 3 Add purified water while mixing.
• Step 4 Screen the wet granules from Step 3.
• Step 5 Transfer the granules from Step 4 into a suitable dryer and dry until LOD is no more than 3%.
• Step 6 Screen the granules from Step 5.
• Step 7 Mix colloidal silicon dioxide with granules in Step 6 in a suitable blender.
• Step 8 Mix stearic acid and magnesium stearate with the blend in Step 7 and continue blending.
• Step 9 Compress the final blend in Step 8 on a suitable rotary tablet press.
• Formulation SR-1 An alternate 25 mg sustained-release formulation of ruxolitinib phosphate has been prepared as described below. The formulation components are provided in Table lb.
• conversion factor for phosphate salt to free base is 0.7575.
• Step 1 Add microcrystalline cellulose, ruxolitinib phosphate, lactose monohydrate, and hypromelloses to a suitable blender and mix.
• Step 2 Transfer the mix from Step 1 to a suitable granulator and mix.
• Step 3 Add purified water while mixing.
• Step 4 Screen the wet granules from Step 3.
• Step 5 Transfer the granules from Step 4 into a suitable dryer and dry until LOD is no more than 3%.
• Step 6 Screen the granules from Step 5.
• Step 7 Mix colloidal silicon dioxide with granules in Step 6 in a suitable blender.
• Step 8 Mix stearic acid and magnesium stearate with the blend in Step 7 and continue blending.
• Step 9 Compress the final blend in Step 8 on a suitable rotary tablet press.
• Immediate-release dosage forms of ruxolitinib phosphate can be obtained commercially in 5, 10, 15, 20, and 25 mg doses as the drug product Jakafi® (ruxolitinib phosphate (tablets)) (NDA no. N202192).
• the commercially available dosage forms are the same as used in the Phase 3 COMFORT- 1 and COMFORT-II studies.
• This study was performed to evaluate pharmacokinetic performance of two ruxolitinib phosphate sustained release (SR) formulations compared to the ruxolitinib phosphate immediate release (IR) tablets.
• the study was conducted as a 3-period study in which each subject received the IR tablets, the SR-1 tablets and the SR-2 tablets, all in fasted state. All treatments were administered as a single dose in one tablet.
• Nine healthy subjects enrolled in this study received IR tablets in Period 1, and 8 subjects continued on the study were randomized into 2 sequences to receive SR-1 and SR-2 tablets in Period 2 and Period 3.
• Blood samples for determination of plasma concentrations of ruxolitinib were collected at 0, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24 and 36 hours post-dose using lavender top (K2EDTA) Vacutainer® tubes. No samples were collected for determination of urine concentrations of ruxolitinib.
• Plasma and urine samples were shipped to Incyte Corporation for determination of ruxolitinib concentrations.
• the plasma samples were assayed by validated, GLP,
• Standard non-compartmental pharmacokinetic methods were used to analyze the ruxolitinib plasma concentration data using Phoenix WinNonlin version 6.0 (Pharsight Corporation, Mountain View, CA). Thus, C max and T max were taken directly from the observed plasma concentration data.
• the absorption lag time (Ti ag ) was defined as the sampling time immediately preceding that corresponding to the first measurable (non-zero) concentration.
• the terminal-phase disposition rate constant ( ⁇ ⁇ ) was estimated using a log- linear regression of the concentration data in the terminal disposition phase, and ti/2 was estimated as 1 ⁇ (2)/ ⁇ ⁇ .
• AUCo-t was estimated using the linear trapezoidal rule for increasing concentrations and the log-trapezoidal rule for decreasing concentrations, and the total AUCo- oo was calculated as AUCo-t + C t / -
• the oral-dose clearance (Cl/F) was estimated as
• the log-transformed pharmacokinetic parameters were compared among the treatments using a 2 -factor ANOVA with the fixed factor for treatment and random factor for subject.
• the relative bioavailability of the fasted administration of the SR formulations (test treatments) compared to fasted administration of the IR tablets (reference treatment) were estimated using the geometric mean relative bioavailability and 90% confidence intervals for Cmax, AUCo-t and AUCo- ⁇ , which were calculated from the adjusted means (least square means) from the ANOVA. All statistical analyses were performed using SAS version 9.1 (SAS Institute, Inc., Cary, NC).
• SR-2 sustained-release formulation
• All patients were treated with 25 mg once daily doses for 8 weeks. After 8 weeks, depending upon the clinical response, the investigator was allowed to (a) maintain the same dose of SR-2, (b) increase the dose to 50 mg once daily, (c) increase the dose to alternating doses of 25 mg and 50 mg, dosed once daily, or (d) switch to treatment with the immediate release formulation.
• Part 1 evaluated two dose levels of 25 mg bid and 50 mg bid
• Part 2 studied five dose regimens of 10 mg bid, 25 mg bid, 25 mg qd, 50 mg qd and 100 mg qd
• Part 3 assessed six dose regimens of 10 mg bid, 15 mg bid, 25 mg bid, 50 mg qd, 100 mg qd and 200 mg qd.
• pharmacokinetic samples were collected at pre-dose and 0.5, 1, 1.5, 2, 4, 6 and 9 hours post-dose on Day 15 of Cycle 1 and at pre-dose on Day 1 of Cycles 2 and 3.
• the pharmacokinetic samples were collected at pre-dose and 2 hours after administration of the morning dose of ruxolitinib on Day 15 of Cycle 1 and Day 1 of Cycles 2 and 3.
• Plasma concentration data from Cycle 1 for subjects in Part 1 and 2 were used for non-compartmental analysis while all plasma concentration data were used for population PK analysis.
• Table 4b The study was comprised of 3 parts: Part 1-dose escalation and expansion cohort, bid dosing, Part 2- alternative dosing schedules (A, B and C), and Part 3 -three independent patient groups (Group I, II and III). Schedules A, B and C in Part 2 were once daily (qd) dosing regimens, low dose regimen of 10 mg bid and induction/maintenance regimen, respectively. Part 3 was studied in three separate groups of patients to further evaluate the safety and efficacy of selected starting dose levels and to explore dose modification on an individual patient basis as appropriate. Dose hold and withdrawal for safety were defined in terms of platelet count and absolute neutrophil count (ANC) while provision for dose increase was provided based on inadequate efficacy defined by change in spleen size.
• ANC absolute neutrophil count
• Ruxolitinib phosphate tablets (5 and 25 mg) were administered as oral doses with water in an outpatient setting. Doses ranged from 10 mg bid to 50 mg bid, and from 25 mg qd to
• pharmacokinetic samples were collected at pre-dose and 0.5, 1, 1.5, 2, 4, 6 and 9 hours post-dose on Day 15 of Cycle 1 and at pre-dose on Day 1 of Cycles 2 and 3.
• the pharmacokinetic samples were collected at pre-dose and 2 hours after administration of the morning dose on Day 15 of Cycle 1 and Day 1 of Cycles 2 and 3.
• Plasma samples were shipped to Incyte Corporation and assayed by a validated, GLP, LC/MS/MS method with a linear range of 1 to 1000 nM and a limit of quantification of 1 nM.
• C max and T max were taken directly from the observed plasma concentration data.
• the terminal-phase disposition rate constant ( ⁇ ⁇ ) was estimated using a log-linear regression of the concentration data in the terminal disposition phase, and ti /2 was estimated as 1 ⁇ (2)/ ⁇ ⁇ .
• AUCo- t was estimated using the linear-trapezoidal rule for increasing concentrations and the log-trapezoidal rule for decreasing concentrations, and the total AUCo- ⁇ was calculated as AUCo-t + C Z .
• the oral-dose clearance (Cl/F) was estimated as Dose/ AUCo- ⁇
• the terminal-phase volume of distribution (V z /F) was estimated as Dose/[ AUCo- ⁇ * ⁇ ⁇ ].
• ⁇ ⁇ was estimated using a log-linear regression of the concentration data in the terminal disposition phase, and ti/2 was estimated as ln(2)/ ⁇ ⁇ .
• the AUC over one dosing interval (AUCo-i2h for ql2h administration, or AUCo-24h for q24h administration) was estimated using the linear trapezoidal rule for increasing concentrations and the log-trapezoidal rule for decreasing concentrations.
• the Cl/F was estimated as Dose/AUC
• V z /F was estimated as Dose/[AUC* ⁇ ⁇ ].
• the Cmin and AUCo-t (Area under the steady-state plasma concentration-time curve from time zero to the time of the last sample obtained) were calculated for the multiple-dose data.
• the PK parameters of ruxolitinib were summarized for each dose group using descriptive statistics, and the log-transformed ruxolitinib PK parameters were compared among the dose groups using a 1-factor analysis of variance.
• ruxolitinib The pharmacokinetics of ruxolitinib in MF patients was similar to that in healthy volunteers.
• Enlarged spleen is a common and prominent symptom of myelofibrosis. Reduction in spleen volume serves as a measure for assessing the effectiveness of a given treatment.
• Table 5a reports the mean reduction in spleen volume in MF patients enrolled in the sustained- release study (See Example 3) at 16 weeks of treatment, while Table 5b reports the mean reduction in spleen volume in MF patients enrolled in the COMFORT-I study (immediate release, see Comparative Example A) at 24 weeks of treatment.
• both the sustained-release and immediate release treatment regimens were effective in reducing spleen volume.
• Effectiveness of a treatment regimen in an MF patient can also be assessed by Total Symptom Score.
• symptoms of MF were assessed using a symptom diary (modified MFSAF v2.0 diary) where subjects recorded answers to queries regarding MF symptoms on a handheld device. Symptoms assessed included filling up quickly/early satiety, abdominal discomfort, abdominal pain, inactivity, night sweats, itching, and bone/muscle pain.
• Table 5c reports the Total Symptom Score results in the sustained-release study (see Example 3) while Table 5d reports the Total Symptom Score results in the COMFORT-I study (immediate-release, see Comparative Example A) at 24 weeks.
• both the SR and IR regimens were effective at treating MF in patients.
• Adverse events are graded according to CTCAE criteria which can be found online at ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm or evs.nci.nih.gov/ftpl/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
• a Grade 3 adverse event generally corresponds to a reaction that is severe or medically significant, but not immediately life-threatening where hospitalization or prolongation of hospitalization is indicated and where the reaction is disabling to the extent of limiting self care. Higher Grades are 4 (life-threatening requiring urgent intervention) and 5 (death). For anemia, Grade 3 corresponds to Hgb ⁇ 8.0 g/dL; ⁇ 4.9 mmol/L; ⁇ 80 g/L, where a transfusion is indicated. For thrombocytopenia (decreased platelet count), Grade 3 corresponds to ⁇ 50,000- 25,000/mm 3 ; ⁇ 50.0-25.0xl0 9 /L. The sustained-release data was evaluated for patients over the course of 16 weeks. Mean duration of exposure to ruxolitinib in the COMFORT-I was approximately 242 days. Typically, the majority of hematologic adverse events occur within the first few months of therapy as observed in the COMFORT-I study.
• Tables 6b and 6c report the number and percentage of patients in the studies exhibiting certain reactions including anemia and thrombocytopenia.
• the sustained-release data was evaluated for patients over the course of 16 weeks. Mean duration of exposure to ruxolitinib in the COMFORT-I study was approximately 242 days. The vast majority of hematologic adverse events occur within the first few months of therapy as observed in the COMFORT-I study. As can be seen from the data in the tables, the number and percentage of patients exhibiting blood-related adverse events is lower in the sustained-release study. Additionally, the severity of the adverse events is lesser in the sustained-release study.
• myelofibrosis patients In this double-blind trial, patients with intermediate-2 or high risk myelofibrosis were randomly assigned to twice-daily oral, immediate-release (see Example 1) ruxolitinib (155 patients) or placebo (154 patients).
• the starting dose of ruxolitinib depended on the baseline platelet count: 15 mg twice daily for a platelet count of 100x 109 to 200x 109 per liter and 20 mg twice daily for a count that exceeded 200x 109 per liter. The dose was adjusted for lack of efficacy or excess toxicity.
• the primary end point was the proportion of patients with a reduction in spleen volume of 35% or more at 24 weeks, assessed by means of magnetic resonance imaging. Secondary end points included the durability of response, changes in symptom burden (assessed by the total symptom score), and overall survival.
• the proportion of patients with a reduction of 35% or more in spleen volume at week 24 was 41.9% in the ruxolitinib group as compared with 0.7% in the placebo group.
• Myelofibrosis patients were randomly assigned, in a 2: 1 ratio, to receive ruxolitinib or the best available therapy, which included any commercially available agents (as
• the starting dose of ruxolitinib tablets was 15 mg twice daily of an immediate release formulation (See Example 1) if the baseline platelet count was 200x 109 per liter or less and 20 mg orally twice daily if the baseline platelet count was greater than 200x 109 per liter.
• the primary end point was a reduction of 35% or more in spleen volume from baseline at week 48. At week 48, most of the patients in the ruxolitinib group had a reduction in spleen volume. Only patients in the ruxolitinib group met the criterion for the primary end point,

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Physical Education & Sports Medicine (AREA)
• Immunology (AREA)
• Diabetes (AREA)
• Virology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Rheumatology (AREA)
• Hematology (AREA)
• Neurology (AREA)
• Oncology (AREA)
• Epidemiology (AREA)
• Communicable Diseases (AREA)
• Endocrinology (AREA)
• Obesity (AREA)
• Biomedical Technology (AREA)
• Molecular Biology (AREA)
• Neurosurgery (AREA)
• Urology & Nephrology (AREA)
• Dermatology (AREA)
• Cardiology (AREA)
• Ophthalmology & Optometry (AREA)
• Pulmonology (AREA)
• Heart & Thoracic Surgery (AREA)
• Nutrition Science (AREA)
• Tropical Medicine & Parasitology (AREA)
• Hospice & Palliative Care (AREA)

Priority Applications (41)

Applications Claiming Priority (4)

Publications (1)

Family

ID=49681181

Family Applications (1)

Country Status (34)

Cited By (14)

Families Citing this family (52)

Citations (1)

Family Cites Families (307)

• 2013
  • 2013-11-14 KR KR1020157015681A patent/KR102242077B1/ko active Active
  • 2013-11-14 TW TW109114623A patent/TWI761825B/zh active
  • 2013-11-14 NZ NZ748448A patent/NZ748448A/en unknown
  • 2013-11-14 RS RS20210982A patent/RS62329B1/sr unknown
  • 2013-11-14 CN CN202110377873.4A patent/CN113384546A/zh active Pending
  • 2013-11-14 CN CN201380070296.8A patent/CN105007901A/zh active Pending
  • 2013-11-14 TW TW102141524A patent/TWI702057B/zh active
  • 2013-11-14 BR BR112015010663-3A patent/BR112015010663B1/pt active IP Right Grant
  • 2013-11-14 IL IL297429A patent/IL297429A/en unknown
  • 2013-11-14 KR KR1020227040652A patent/KR20220162825A/ko not_active Ceased
  • 2013-11-14 HU HUE13798840A patent/HUE055894T2/hu unknown
  • 2013-11-14 CR CR20190073A patent/CR20190073A/es unknown
  • 2013-11-14 IL IL291391A patent/IL291391B/en unknown
  • 2013-11-14 PE PE2019001988A patent/PE20200175A1/es unknown
  • 2013-11-14 PE PE2015000624A patent/PE20151157A1/es not_active Application Discontinuation
  • 2013-11-14 SG SG11201503695XA patent/SG11201503695XA/en unknown
  • 2013-11-14 TW TW111113106A patent/TW202228704A/zh unknown
  • 2013-11-14 IL IL328652A patent/IL328652A/en unknown
  • 2013-11-14 MY MYPI2015001254A patent/MY191357A/en unknown
  • 2013-11-14 PH PH1/2020/551186A patent/PH12020551186B1/en unknown
  • 2013-11-14 KR KR1020217009090A patent/KR20210037012A/ko not_active Ceased
  • 2013-11-14 SG SG10201703685UA patent/SG10201703685UA/en unknown
  • 2013-11-14 TW TW107133083A patent/TW201922255A/zh unknown
  • 2013-11-14 CN CN202110377848.6A patent/CN113384545A/zh active Pending
  • 2013-11-14 EP EP13798840.8A patent/EP2919766B1/en active Active
  • 2013-11-14 ES ES13798840T patent/ES2880814T3/es active Active
  • 2013-11-14 HR HRP20211158TT patent/HRP20211158T1/hr unknown
  • 2013-11-14 AU AU2013344780A patent/AU2013344780B2/en active Active
  • 2013-11-14 NZ NZ708157A patent/NZ708157A/en unknown
  • 2013-11-14 UA UAA201505798A patent/UA120834C2/uk unknown
  • 2013-11-14 LT LTEP13798840.8T patent/LT2919766T/lt unknown
  • 2013-11-14 PL PL13798840T patent/PL2919766T3/pl unknown
  • 2013-11-14 SI SI201331922T patent/SI2919766T1/sl unknown
  • 2013-11-14 SM SM20210436T patent/SMT202100436T1/it unknown
  • 2013-11-14 CA CA3178452A patent/CA3178452A1/en active Pending
  • 2013-11-14 AR ARP130104195A patent/AR093490A1/es not_active Application Discontinuation
  • 2013-11-14 JP JP2015542764A patent/JP2015537030A/ja active Pending
  • 2013-11-14 EA EA201590930A patent/EA201590930A1/ru unknown
  • 2013-11-14 IL IL317061A patent/IL317061A/en unknown
  • 2013-11-14 EP EP21174620.1A patent/EP3949953A1/en active Pending
  • 2013-11-14 DK DK13798840.8T patent/DK2919766T3/da active
  • 2013-11-14 US US14/079,901 patent/US10166191B2/en active Active
  • 2013-11-14 CA CA2890755A patent/CA2890755C/en active Active
  • 2013-11-14 SG SG10202111768XA patent/SG10202111768XA/en unknown
  • 2013-11-14 WO PCT/US2013/070012 patent/WO2014078486A1/en not_active Ceased
  • 2013-11-14 MX MX2020012676A patent/MX2020012676A/es unknown
  • 2013-11-14 PT PT137988408T patent/PT2919766T/pt unknown
  • 2013-11-14 MX MX2015005947A patent/MX380147B/es unknown
• 2015
  • 2015-05-11 IL IL238765A patent/IL238765B/en unknown
  • 2015-05-12 MX MX2023000255A patent/MX2023000255A/es unknown
  • 2015-05-12 CL CL2015001286A patent/CL2015001286A1/es unknown
  • 2015-05-15 PH PH12015501089A patent/PH12015501089A1/en unknown
  • 2015-05-19 CR CR20150265A patent/CR20150265A/es unknown
• 2018
  • 2018-06-01 AU AU2018203899A patent/AU2018203899B2/en active Active
  • 2018-11-14 US US16/190,883 patent/US10874616B2/en active Active
• 2019
  • 2019-03-05 JP JP2019039497A patent/JP6975738B2/ja active Active
• 2020
  • 2020-02-12 AU AU2020201011A patent/AU2020201011B2/en active Active
  • 2020-11-16 US US17/098,913 patent/US11337927B2/en active Active
• 2021
  • 2021-04-15 JP JP2021069078A patent/JP7225299B2/ja active Active
  • 2021-08-19 CY CY20211100742T patent/CY1124446T1/el unknown
• 2022
  • 2022-03-07 ZA ZA2022/02711A patent/ZA202202711B/en unknown
  • 2022-03-08 AU AU2022201582A patent/AU2022201582A1/en not_active Abandoned
  • 2022-03-23 US US17/702,315 patent/US20220211631A1/en not_active Abandoned
  • 2022-06-23 US US17/847,760 patent/US11576865B2/en active Active
  • 2022-06-23 US US17/847,734 patent/US11576864B2/en active Active
  • 2022-12-29 US US18/090,547 patent/US11896717B2/en active Active
• 2023
  • 2023-02-08 JP JP2023017676A patent/JP7577146B2/ja active Active
• 2024
  • 2024-11-08 US US18/941,410 patent/US20250064746A1/en not_active Abandoned
• 2025
  • 2025-06-18 US US19/241,848 patent/US20250312279A1/en active Pending

Patent Citations (1)

Non-Patent Citations (4)